VIVUS (STU:VIU1) Accounts Payable & Accrued Expense : €24.05 Mil (As of Mar. 2020)

View and export this data going back to . Start your Free Trial

What is VIVUS Accounts Payable & Accrued Expense?

VIVUS's quarterly accounts payable & accrued expense declined from Sep. 2019 (€21.67 Mil) to Dec. 2019 (€20.23 Mil) but then increased from Dec. 2019 (€20.23 Mil) to Mar. 2020 (€24.05 Mil).

VIVUS's annual accounts payable & accrued expense increased from Dec. 2017 (€16.94 Mil) to Dec. 2018 (€21.53 Mil) but then declined from Dec. 2018 (€21.53 Mil) to Dec. 2019 (€20.23 Mil).

VIVUS Accounts Payable & Accrued Expense Historical Data

The historical data trend for VIVUS's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VIVUS Accounts Payable & Accrued Expense Chart

VIVUS Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

17.75

16.48

16.94

21.53

20.23

VIVUS Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															19.71	19.82	21.67	20.23	24.05

VIVUS Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

VIVUS (STU:VIU1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VIVUS Inc (STU:VIU1) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

900 East Hamilton Avenue, Suite 550, Campbell, CA, USA, 95008

Website

http://www.vivus.com

VIVUS Inc is a US-based biopharmaceutical company engaged in developing and commercializing, next-generation therapies to address unmet medical needs in human health. Its commercial products include Qsymia, an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index; PANCREAZE which is a is a pancreatic enzyme preparation consisting of pancrelipase, an extract derived from porcine pancreatic glands, as well as other enzyme classes and STENDRA/SPEDRA, which is an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.

VIVUS (STU:VIU1) Headlines

No Headlines